ESMO 2022 | Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer

Evandro De Azambuja, MD, PhD, Jules Bordet Institute, Brussels, Belgium, discusses the prognostic value of tumor infiltrating lymphocytes (TILs) in breast cancer. HER2-positive breast cancer with a high level of TILs often respond better to HER2-targeting agents, and triple-negative breast cancer with high levels of TILs respond better to chemotherapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.